Modern trend
The FMR1 premutation and reproduction

https://doi.org/10.1016/j.fertnstert.2006.09.004Get rights and content
Under an Elsevier user license
open archive

Objective

To update clinicians on the reproductive implications of premutations in FMR1 (fragile X mental retardation 1). Fragile X syndrome, a cause of mental retardation and autism, is due to a full mutation (>200 CGG repeats). Initially, individuals who carried the premutation (defined as more than 55 but less than 200 CGG repeats) were not considered at risk for any clinical disorders. It is now recognized that this was incorrect, specifically with respect to female reproduction.

Design and Setting

Literature review and consensus building at two multidisciplinary scientific workshops.

Conclusion(s)

Convincing evidence now relates the FMR1 premutation to altered ovarian function and loss of fertility. An FMR1 mRNA gain-of-function toxicity may underlie this altered ovarian function. There are major gaps in knowledge regarding the natural history of the altered ovarian function in women who carry the FMR1 premutation, making counseling about reproductive plans a challenge. Women with premature ovarian failure are at increased risk of having an FMR1 premutation and should be informed of the availability of fragile X testing. Specialists in reproductive medicine can provide a supportive environment in which to explain the implications of FMR1 premutation testing, facilitate access to testing, and make appropriate referral to genetic counselors.

Key Words

Fragile X syndrome
FMR1
premutation
spontaneous premature ovarian failure
hypergonadotropic hypogonadism
primary hypogonadism
primary ovarian insufficiency
premature menopause
hypergonadotropic amenorrhea
low response to gonadotropin stimulation
diminished ovarian reserve
fragile X–associated tremor/ataxia syndrome
FXTAS
genetic counseling

Cited by (0)

Supported by the American Society for Reproductive Medicine; the Intramural Research Program of the National Institute of Child Health and Human Development, Office of Rare Diseases, Office of Research on Women’s Health, and the National Institute of Mental Health, National Institutes of Health; and by Centers for Disease Control and Prevention grant (U10/CCU 92513).